SUPG gives Orathecin, Dacogen updates

SuperGen (SUPG) withdrew its NDA for Orathecin rubitecan to treat pancreatic cancer based on feedback from FDA

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE